Skip to main content
Oculis Holding AG logo

Oculis Holding AG — Investor Relations & Filings

Ticker · OCS ISIN · CH1242303498 LEI · 5067005370C2KK324336 IC Manufacturing
Open in API
Filings indexed 317 across all filing types
Latest filing 2026-03-31 Regulatory Filings
Country CH Switzerland
Listing IC OCS

About Oculis Holding AG

https://www.oculis.com/

Oculis Holding AG is a global, clinical-stage biopharmaceutical company focused on developing innovative therapies for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs. The company's pipeline aims to transform current treatment paradigms. Key candidates include OCS-01, a topical eye drop using the proprietary OPTIREACH® technology, investigated as a potential first non-invasive treatment for Diabetic Macular Edema (DME). Another lead asset is Privosegtor, a novel peptoid small molecule being developed as a neuroprotective therapy for optic neuropathies such as Acute Optic Neuritis. The pipeline also features Licaminlimab, an anti-TNFα eye drop candidate for treating Dry Eye Disease.

Recent filings

Filing Released Lang Actions
Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis
Regulatory Filings Classification · 75% confidence The document is a corporate press release announcing that the company’s drug candidate has received EMA PRIME designation. It is not an earnings release, annual or interim report, management or board change announcement, proxy statement, or other structured financial filing. It does not present full financial results or detailed regulatory filings, but is a standalone regulatory milestone announcement distributed via GlobeNewswire. Since no specific category for regulatory designations exists, it falls into the general “Regulatory Filings” fallback category (RNS).
2026-03-31 English
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
Director's Dealing Classification · 90% confidence The document is a notification of transactions by persons discharging managerial responsibilities (PDMRs), detailing an insider equity award transaction by an executive committee member. This matches the definition of Director’s Dealing (insider share transactions by directors/executives), Code DIRS.
2026-03-27 English
SCHEDULE 13G/A - Oculis Holding AG (0001953530) (Subject)
Major Shareholding Notification
2026-03-27 English
Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Oculis Holding AG will present clinical trial data (ACUITY Phase 2) at an upcoming medical conference (NANOS 2026). It provides details on the study, the drug candidate (Privosegtor), and the company's pipeline. It does not fit into specific financial reporting categories like 10-K or IR, nor is it a simple report publication announcement. As it is a general corporate announcement regarding clinical progress and conference participation, it falls under the 'Regulatory Filings' (RNS) category as the fallback for general corporate news.
2026-03-16 English
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
Director's Dealing Classification · 100% confidence The document is a short announcement (618 characters) titled 'Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities'. It explicitly states that the 'attached notifications relate to the purchase of ordinary shares by a member of the Company’s Board of Directors'. Since this is a notification of a director's share transaction, it falls under the 'Director's Dealing' category (DIRS).
2026-03-16 English
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
Director's Dealing Classification · 100% confidence The document is a short announcement regarding 'Notifications of Transactions by Persons Discharging Managerial Responsibilities' (PDMRs). It explicitly mentions that the notifications relate to trades by an executive committee member under a 10b5-1 trading plan. In financial reporting, disclosures of personal share transactions by directors and executives are classified as Director's Dealing.
2026-03-13 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.